SXTP

After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blindedAs of the same date, the Company had enrolled 30 patientsGiven the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027No safety signals were identified in the studyPublished case reports and the Company’s prospective expanded

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier. WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis (NCT06207370

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

– On-demand company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET – – Management will be available for one-on-one investor meetings during the conference – WASHINGTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York City. A pre-recorded presentation by 60 Degrees Pharmaceuticals will be available on demand here to registered confe

EFFECT - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

DEL AM - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

S-3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026. Financial Highlights for the Quarter Ended June 30, 2026: Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 20

10-Q - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,713 shares of its common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 574,713 shares of common stock and short-term series B warrants to purchase up to 574,713 shares of common stock at a purchase price of $1.74 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement

3 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

SCHEDULE 13G - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Subject)

Company plans to request an FDA meeting following the interim readout to discuss the regulatory pathway for a New Drug Application (NDA) for tafenoquine in babesiosis WASHINGTON, July 29, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced it has enrolled the minimum 24 patients needed to trigger an interim analysis in its clinical study of patients hospitalized with severe babesiosis (NCT06207370). The outcome of the interim analysis will be disclosed no later than October 6, 2026. Enrollment will continue in the in

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme diseaseAgreement builds on Company's expertise in vector-borne diseases and complements ongoing development of tafenoquine for babesiosisCompany continues to evaluate multiple regulatory pathways for castanospermine while prioritizing prescription drug development WASHINGTON, July 08, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced tha

DEF 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (NCT06656351), following a review of safety data from the first six patients from baseline through Day 30. The B-Free study is evaluating recovery from fatigue following treatment with the ARAKODA® regimen of tafenoquine (loading dose of 200 mg per day for four days, then 200 mg weekly through Day 90) in patients with severe persiste

4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S. WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scal

PRE 14A - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)